Krsnaa Diagnostics (KRSNAA) Q2 25/26 earnings summary

Executive summary

• Achieved 11% year-on-year revenue growth in Q2 FY26, reaching INR 2,060 million, with strong performance in radiology and pathology segments.

• PAT reached an all-time high of INR 239 million in Q2 FY26, up 22% year-on-year, with margins expanding to 12%.

• Retail business revenue surged 60% quarter-on-quarter, now contributing 8% of revenues, with touch points up 4.7x year-over-year.

• Served approximately 5.4 million patients in Q2 FY26, reflecting a 4% increase year-on-year.

• Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

Financial highlights

• Consolidated revenue for Q2 FY26: INR 2,059.91 million, up 11% year-on-year.

• EBITDA grew 18% year-on-year to INR 602 million, with margin at 29% (221 bps expansion).

• PAT for Q2 FY26: INR 239 million, up 22% year-on-year; margin at 12%.

• EPS for Q2 FY26: INR 7.38, up 24% year-on-year.

• Receivables at 150 days, targeted to reduce to 100 days by year-end.

Outlook and guidance

• Rajasthan PPP project to operationalize 10 labs in November, 25 labs and 500 collection centers by December, and remaining by end of Q4.

• Full-year revenue contribution from new PPP projects expected in FY27.

• Retail revenue share expected to rise to 15-20% in the coming year and 40-50% over five years.

• Guidance for overall revenue growth in the high teens for the next year.

• Management expects ongoing tax proceedings will not materially impact financial position.